Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Category
Cancer
Sub Category
Gynecologic
Study Name
NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Principal Investigator
Gordan Srkalovic MD, PhD
Study Information
https://www.clinicaltrials.gov/ct2/show/NCT02502266?term=GY005&rank=2
Contact for Questions
Nurse - Tracy 517-364-2835

Site view: at a glance